SHINE has completed the acquisition of Lantheus' SPECT business, including its manufacturing facility in North Billerica, Massachusetts. This acquisition enhances SHINE's position in the nuclear medicine market, which is valued at $19 billion, and integrates established products like TechneLite® and Cardiolite®. Michael Rossi has been appointed as CEO of SHINE SPECT USA, LLC to lead the integration and growth of the SPECT business.
Sign in to access complete coverage, AI analysis, and related companies.
Sign In to Continue